{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:11:53Z","timestamp":1791357113110,"version":"4.3.1"},"reference-count":50,"publisher":"Cambridge University Press (CUP)","issue":"6","license":[{"start":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T00:00:00Z","timestamp":1415318400000},"content-version":"unspecified","delay-in-days":1985,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS spectr."],"published-print":{"date-parts":[[2009,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Introduction:<\/jats:bold> Once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy was evaluated in major depressive disorder (MDD).<\/jats:p><jats:p><jats:bold>Method:<\/jats:bold> This was an 8-week (6-week randomized-phase; 2-week drug-discontinuation\/tapering phase), double-blind, parallel-group, placebo-controlled study. The primary outcome measure was Montgomery-\u00c5sberg Depression Rating Scale (MADRS) total score randomization-to-Week 6 change. Other assessments included the Hamilton Rating Scale for Depression, the Hamilton Rating Scale for Anxiety, and adverse events (AEs).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> 723 patients were randomized: 182, 178, 179, and 184 to quetiapine XR 50, 150, 300 mg\/day, and placebo, respectively. At Week 6, significant reductions occurred in MADRS score with quetiapine XR 50 mg\/day (\u221213.56; <jats:italic>P<\/jats:italic>&lt;.05), 150 mg\/day (\u221214.50; <jats:italic>P<\/jats:italic>&lt;.01) and 300 mg\/day (\u221214.18; <jats:italic>P<\/jats:italic>&lt;.01) versus placebo (\u221211.07); at Day 4, reductions for quetiapine XR (titrated to 50 or 150 mg\/day according to dose group) versus placebo (\u22122.9) were: \u22124.7 (<jats:italic>P<\/jats:italic>&lt;.01), \u22125.2 (<jats:italic>P<\/jats:italic>&lt;.001), and \u22125.1 (<jats:italic>P<\/jats:italic>&lt;.001), respectively. At endpoint, MADRS response (\u226550% reduction in score) was 42.7% (<jats:italic>P<\/jats:italic>&lt;.01), 51.2% (<jats:italic>P<\/jats:italic>&lt;.001), and 44.9% (<jats:italic>P<\/jats:italic>\u2264.001) for quetiapine XR 50, 150, and 300 mg\/day, respectively; 30.3% for placebo. Overall, quetiapine XR 150 mg\/day provided consistently more positive secondary efficacy results than 50 mg\/day and 300 mg\/day versus placebo. The most common AEs in quetiapine XR-treated patients were dry mouth, sedation, somnolence, headache, and dizziness.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> In patients with MDD, quetiapine XR monotherapy (50\/150\/300 mg\/day) is effective in reducing depressive symptoms, with improvement from Day 4 onwards. Safety and tolerability were consistent with the known profile of quetiapine.<\/jats:p>","DOI":"10.1017\/s1092852900020307","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T01:06:24Z","timestamp":1470099984000},"page":"299-313","source":"Crossref","is-referenced-by-count":86,"title":["Extended Release Quetiapine Fumarate Monotherapy for Major Depressive Disorder: <i>Results of a Double-Blind, Randomized, Placebo-Controlled Study<\/i>"],"prefix":"10.1017","volume":"14","author":[{"given":"Richard","family":"Weisler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Mark","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lora","family":"McGill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Szamosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Moonstone Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2014,11,7]]},"reference":[{"key":"S1092852900020307_ref018","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0510"},{"key":"S1092852900020307_ref015","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)89080-3"},{"key":"S1092852900020307_ref012","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61238-0"},{"key":"S1092852900020307_ref009","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.3.338"},{"key":"S1092852900020307_ref003","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0211"},{"key":"S1092852900020307_ref006","unstructured":"Hospital stays related to mental health, 2006. Available at: http:\/\/www.hcupus.ahrq.gov\/reports\/statbriefs\/sb62.pdf. Accessed November 7, 2008."},{"key":"S1092852900020307_ref005","first-page":"27","article-title":"Major depressive disorder: remission of associated symptoms","volume":"67","author":"Trivedi","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"S1092852900020307_ref004","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n1102"},{"key":"S1092852900020307_ref026","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2008.09.026"},{"key":"S1092852900020307_ref001","first-page":"8","article-title":"Limitations in efficacy of antidepressant monotherapy","volume":"68","author":"Rush","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"S1092852900020307_ref050","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2007.00520.x"},{"key":"S1092852900020307_ref029","first-page":"332","article-title":"Double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD) [abstract]","volume":"12","author":"Earley","year":"2008","journal-title":"Int J Psychiatry Clin Pract"},{"key":"S1092852900020307_ref016","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.7.1351"},{"key":"S1092852900020307_ref027","unstructured":"Seroquel (quetiapine fumarate) US prescribing information. Available at: http:\/\/www1.astrazeneca-us.com\/pi\/seroquel.pdf. Accessed May 1, 2009."},{"key":"S1092852900020307_ref019","first-page":"59","article-title":"A double-blind, placebo-controlled study with acute and continuation phase of quetiapine and paroxetine in adults with bipolar depression (EMBOLDEN II) [abstract]","volume":"10","author":"McElroy","year":"2008","journal-title":"Bipolar Disord"},{"key":"S1092852900020307_ref033","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1994"},{"key":"S1092852900020307_ref049","article-title":"Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR","author":"Hewett","year":"2008","journal-title":"J Psychopharmacol"},{"key":"S1092852900020307_ref007","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-6-200509200-00006"},{"key":"S1092852900020307_ref014","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n1211"},{"key":"S1092852900020307_ref034","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"S1092852900020307_ref017","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000248603.76231.b7"},{"key":"S1092852900020307_ref036","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(98)00126-7"},{"key":"S1092852900020307_ref020","first-page":"187","article-title":"A doubleblind, placebo-controlled study with acute and continuation phase of quetiapine and lithium in adults with bipolar depression (EMBOLDEN I) [abstract]","volume":"11","author":"Young","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"key":"S1092852900020307_ref010","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2008.01179.x"},{"key":"S1092852900020307_ref002","first-page":"17","article-title":"Prevalence and management of treatment-resistant depression","volume":"68","author":"Nemeroff","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"S1092852900020307_ref008","unstructured":"Suicidal Thoughts, Suicide Attempts, Major Depressive Episode, and Substance Use among Adults. Available at: http:\/\/www.oas.samhsa.gov\/2k6\/suicide\/suicide. pdf. Accessed August 20, 2008."},{"key":"S1092852900020307_ref031","first-page":"337","article-title":"Efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder (MDD) [abstract]","volume":"12","author":"Katila","year":"2008","journal-title":"Int J Psychiatr Clin Pract"},{"key":"S1092852900020307_ref021","unstructured":"Weisler RH , Nolen WA , Neijber A , Hellqvist A , Paulsson B . Quetiapine or lithium versus placebo for maintenance treatment of bipolar I disorder after stabilization on quetiapine. Poster presented at: the 60th Institute on Psychiatric Services; October 2-5, 2008; Chicago, IL."},{"key":"S1092852900020307_ref023","unstructured":"El-Khalili N , Joyce M , Atkinson S , Buynak R , Datto C , Lindgren P , Eriksson H , Brecher M . Adjunctive extended release quetiapine fumarate (quetiapine XR) in patients with major depressive disorder and inadequate antidepressant response. Poster presented at: the 161st Annual Meeting of the American Psychiatric Association; May 3-8, 2008; Washington, DC."},{"key":"S1092852900020307_ref024","doi-asserted-by":"publisher","DOI":"10.1002\/da.20275"},{"key":"S1092852900020307_ref011","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0610"},{"key":"S1092852900020307_ref030","unstructured":"El-Khalili N , Banov M , Bortnick B , Adson D , Datto C , Raines S , Earley W , Brecher M . Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder (MDD): a randomized, placebo-controlled clinical trial (Study 003). Poster presented at: the 63rd Annual Society of Biological Psychiatry; May 1-3, 2008; Washington, DC."},{"key":"S1092852900020307_ref028","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04592"},{"key":"S1092852900020307_ref041","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2007.07.005"},{"key":"S1092852900020307_ref032","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(08)70540-6"},{"key":"S1092852900020307_ref035","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.176.4.363"},{"key":"S1092852900020307_ref037","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.54.2.145"},{"key":"S1092852900020307_ref038","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2716"},{"key":"S1092852900020307_ref013","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030442"},{"key":"S1092852900020307_ref022","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04629"},{"key":"S1092852900020307_ref039","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S1248"},{"key":"S1092852900020307_ref040","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2008.07.006"},{"key":"S1092852900020307_ref042","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.11.1905"},{"key":"S1092852900020307_ref043","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301646"},{"key":"S1092852900020307_ref044","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(07)70346-2"},{"key":"S1092852900020307_ref045","doi-asserted-by":"publisher","DOI":"10.1249\/01.mss.0000180883.32116.28"},{"key":"S1092852900020307_ref046","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318166c4d5"},{"key":"S1092852900020307_ref047","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v57n1002"},{"key":"S1092852900020307_ref048","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262040-00010"},{"key":"S1092852900020307_ref025","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.03.002"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852900020307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T09:45:19Z","timestamp":1556617519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852900020307\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S1092852900020307"],"URL":"https:\/\/doi.org\/10.1017\/s1092852900020307","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}